JP2015530087A5 - - Google Patents

Download PDF

Info

Publication number
JP2015530087A5
JP2015530087A5 JP2015529031A JP2015529031A JP2015530087A5 JP 2015530087 A5 JP2015530087 A5 JP 2015530087A5 JP 2015529031 A JP2015529031 A JP 2015529031A JP 2015529031 A JP2015529031 A JP 2015529031A JP 2015530087 A5 JP2015530087 A5 JP 2015530087A5
Authority
JP
Japan
Prior art keywords
species
human
immune library
target antigen
antibody molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015529031A
Other languages
English (en)
Japanese (ja)
Other versions
JP6391574B2 (ja
JP2015530087A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2013/067979 external-priority patent/WO2014033252A1/en
Publication of JP2015530087A publication Critical patent/JP2015530087A/ja
Publication of JP2015530087A5 publication Critical patent/JP2015530087A5/ja
Application granted granted Critical
Publication of JP6391574B2 publication Critical patent/JP6391574B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015529031A 2012-08-31 2013-08-30 種間標的内交差反応性を有する抗体分子を産生する方法 Active JP6391574B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261695664P 2012-08-31 2012-08-31
US61/695,664 2012-08-31
PCT/EP2013/067979 WO2014033252A1 (en) 2012-08-31 2013-08-30 Method for producing antibody molecules having inter-species, intra-target cross-reactivity

Publications (3)

Publication Number Publication Date
JP2015530087A JP2015530087A (ja) 2015-10-15
JP2015530087A5 true JP2015530087A5 (cg-RX-API-DMAC10.html) 2017-09-21
JP6391574B2 JP6391574B2 (ja) 2018-09-26

Family

ID=49080903

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015529031A Active JP6391574B2 (ja) 2012-08-31 2013-08-30 種間標的内交差反応性を有する抗体分子を産生する方法

Country Status (10)

Country Link
US (1) US20150203840A1 (cg-RX-API-DMAC10.html)
EP (2) EP2977386A1 (cg-RX-API-DMAC10.html)
JP (1) JP6391574B2 (cg-RX-API-DMAC10.html)
CN (1) CN104583238A (cg-RX-API-DMAC10.html)
AU (2) AU2013310924B2 (cg-RX-API-DMAC10.html)
CA (1) CA2878712A1 (cg-RX-API-DMAC10.html)
DK (1) DK2890711T3 (cg-RX-API-DMAC10.html)
IL (1) IL236523B (cg-RX-API-DMAC10.html)
IN (1) IN2015DN00140A (cg-RX-API-DMAC10.html)
WO (1) WO2014033252A1 (cg-RX-API-DMAC10.html)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112013021562B1 (pt) 2011-03-16 2023-01-10 Argenx Bvba Anticorpos para cd70
AU2014298373B2 (en) 2013-08-01 2019-12-05 Ludwig Institute For Cancer Research Ltd Anti-GARP protein and uses thereof
US10391168B1 (en) 2014-08-22 2019-08-27 University Of Bern Anti-CD70 combination therapy
WO2018007999A1 (en) 2016-07-08 2018-01-11 Staten Biotechnology B.V. Anti-apoc3 antibodies and methods of use thereof
GB201612337D0 (en) 2016-07-15 2016-08-31 Argen-X N V Ant-il-22r antibodies
WO2018193427A1 (en) 2017-04-21 2018-10-25 Staten Biotechnology B.V. Anti-apoc3 antibodies and methods of use thereof
GB201707561D0 (en) 2017-05-11 2017-06-28 Argenx Bvba GARP-TGF-beta antibodies
CN111315772A (zh) 2017-10-31 2020-06-19 斯塔顿生物技术有限公司 抗apoc3抗体及其使用方法
MX2020006213A (es) 2017-12-12 2020-09-14 Pionyr Immunotherapeutics Inc Anticuerpos anti-trem2 y metodos relacionados.
GB201800649D0 (en) 2018-01-16 2018-02-28 Argenx Bvba CD70 Combination Therapy
US12037382B2 (en) 2018-02-05 2024-07-16 Stichting Vu Inverse agonistic anti-US28 antibodies
WO2020080941A1 (en) 2018-10-16 2020-04-23 Umc Utrecht Holding B.V. Anti- low-density lipoprotein receptor-related protein 5/6 antibodies
WO2021241730A1 (ja) * 2020-05-29 2021-12-02 第一三共株式会社 炎症性腸疾患に対する治療用抗体
WO2022154664A1 (en) 2021-01-15 2022-07-21 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Inducers of senescence, in combination with a selective death receptor 5 (dr5) agonist, for use in a method of treating cancer
EP4612180A1 (en) 2022-10-31 2025-09-10 Stichting Amsterdam UMC Single domain anti-cd169 antibodies
US20260176369A1 (en) 2022-11-08 2026-06-25 Stichting Amsterdam UMC Activation Inducible Antigen Receptors for Adoptive Immunotherapy
EP4631501A1 (en) 2024-04-09 2025-10-15 Stichting Het Nederlands Kanker Instituut- Antoni van Leeuwenhoek Ziekenhuis Combinations of a calcium homeostasis disruptor with a death receptor 5 agonist for treating cancer

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999029888A1 (en) * 1997-12-05 1999-06-17 The Scripps Research Institute Humanization of murine antibody
CN1735629B (zh) * 2002-11-08 2012-05-09 埃博灵克斯股份有限公司 针对肿瘤坏死因子-α的单结构域抗体及其用途
NZ540194A (en) * 2002-11-08 2008-07-31 Ablynx Nv Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor
CN1798768B (zh) * 2003-03-24 2013-05-08 津莫吉尼蒂克斯公司 抗il-22ra抗体和结合伴侣及其应用
DE602004028347D1 (de) * 2003-03-24 2010-09-09 Zymogenetics Inc Anti-il-22ra antikörper und bindungspartner und verwendungsmethoden bei entzündung
ES2335232T3 (es) * 2005-06-21 2010-03-23 Xoma Technology Ltd. Anticuerpos y fragmentos de los mismos que se unen a la il-1 beta.
TWI417301B (zh) * 2006-02-21 2013-12-01 Wyeth Corp 對抗人類介白素-２２（ｉｌ-２２）之抗體及其用途
GB2461546B (en) * 2008-07-02 2010-07-07 Argen X Bv Antigen binding polypeptides
US8444976B2 (en) 2008-07-02 2013-05-21 Argen-X B.V. Antigen binding polypeptides
CA2781682A1 (en) * 2009-12-04 2011-06-09 Genentech, Inc. Multispecific antibodies, antibody analogs, compositions, and methods
GB2476681B (en) 2010-01-04 2012-04-04 Argen X Bv Humanized camelid VH, VK and VL immunoglobulin domains
GB201002238D0 (en) * 2010-02-10 2010-03-31 Affitech As Antibodies
MX385858B (es) * 2010-11-24 2025-03-18 Lexicon Pharmaceuticals Inc Anticuerpos que se unen a notum pectinacetilesterasa.

Similar Documents

Publication Publication Date Title
CN103562403A8 (zh) 识别肿瘤起始细胞的抗体和抗原及其应用
AR108800A1 (es) Purificación de anticuerpos multiespecíficos
EA201690167A1 (ru) Гуманизованные или химерные антитела к cd3
CN111712522A (zh) 抗pd-1/抗vegf天然抗体结构样异源二聚体形式双特异抗体及其制备
JP2012031178A5 (cg-RX-API-DMAC10.html)
EP4223874A3 (en) Human anti-il-33 neutralizing monoclonal antibody
ECSP18043564A (es) Moléculas biespecíficas que tienen inmunorreactividad con pd-1 y ctla-4, y métodos de uso de las mismas
HK1205873A1 (en) Common light chain mouse
EA201690182A1 (ru) АНТИТЕЛА ПРОТИВ ФАКТОРА КОМПЛЕМЕНТА C1q И ИХ ПРИМЕНЕНИЯ
EA201790719A1 (ru) Биспецифические моновалентные диатела, которые способны связывать cd19 и cd3, а также их применения
EA201492137A1 (ru) Антитела к cd33 и их применение в лечении рака
EA201790438A1 (ru) Антигенсвязывающие белки, которые связываются с cxcr5
HK1218550A1 (zh) 常見輕鏈小鼠
WO2016201388A3 (en) Anti-cd33 antibodies and methods of use thereof
AU2013310924A8 (en) Method for producing antibody molecules having inter-species, intra-target cross-reactivity
GT201300149A (es) Proteinas de union al tnf-a
WO2015028454A3 (en) Method for the treatment of fibrotic disease
EA201990894A1 (ru) Анти-pd-1/анти-her2 гетеродимерное биспецифическое антитело со структурой природного антитела и способ его получения
EA201600276A1 (ru) Анти-il-17-антитела, способ их получения и способ применения
MY166794A (en) Antibody and antibody-containing composition
EA201691473A1 (ru) Биспецифические анти-il-13/il-17 антитела и их применение
EA201591347A1 (ru) Способ получения подложки, снабженной покрытием
JP2010513228A5 (cg-RX-API-DMAC10.html)
EA201892716A1 (ru) Антитела к фактору свертывания xi
WO2014189306A8 (ko) 항 ＴＮＦ-α/ＣＸＣＬ10 이중 타겟 항체 및 그의 용도